Enhancing 5-fluorouracil cytotoxicity by inhibiting dihydropyrimidine dehydrogenase activity with uracil in human tumor cells

International Journal of Oncology

Volumn 11, Issue 5, 1997, Pages 1041-1044

  Takechi, Teiji ^a   Uchida, Junji ^a   Fujioka, Akio ^a   Fukushima, Masakazu ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

5 fluorouracil; Biochemical modulation; Dihydropyrimidine dehydrogenase; Enhancement of cytotoxicity; Uracil

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROPYRIMIDINE; FLUOROURACIL; URACIL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY TEST; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; NUDE MOUSE; PRIORITY JOURNAL; RADIOENZYMATIC ASSAY;

EID: 0030853620     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.11.5.1041     Document Type: Article

References (17)

1. Naguib FMN, El Kouni MH and Cha S: Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 45: 5405-5412, 1985.
2. Etienne MC, Cheradame S, Fischel JL, Formento P, Dassonville O, Renee N, Schneider M, Thyss A, Demard F and Milano G: Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 13: 1663-1670, 1995.
3. Okayasu T, Sugiyama K and Miyauchi S: Inhibition of catabolic pathway of 5-fluorourncil by 3-cyano-2,6-dihydroxypyridine in human lung cancer tissues. Jpn J Cancer Res 85: 101-105, 1994.
4. Porter DJT, Chestnut WG, Merrill BM and Spector T: Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil. J Biol Chem 267: 5236-5242, 1992.
5. Spector T, Harrington JA and Porter DJT: 5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo. Biochem Pharmacol 46: 2243-2248, 1993.
6. Toide H, Akiyoshi H, Minato Y, Okuda H and Fujii S: Comparative studies on the metabolism of 2-(tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil. Jpn J Cancer Res 68: 533-540, 1977.
7. Kurihara M, Izumi T, Yoshida S, Ohkubo T, Suga S, Kiyohashi A, Yaosaka T, Takahashi H, Ito T, Sasai T, Akiya T, Akazawa S, Betsuyaku T and Taguchi S: A cooperative randomized study on tegafur plus mitomycin C versus combined tegafur and uracil plus mitomycin C in the treament of advanced gastric cancer. Jpn J Cancer Res 82: 613-620, 1991.
8. Ichinose Y, Takanashi N, Yano T, Asoh H, Yokoyama H, Tayama K, Hara N and Ohta M: A phase II trial of oral tegafur and uracil plus cisplatin in patients with inoperable nonsmall cell lung cancer. Cancer 75: 2677-2680, 1995.
9. Kubota Y, Hosaka M, Fukushima S and Kondo I: Prophylactic oral UFT therapy for superficial bladder cancer. Cancer 71: 1842-1845, 1993.
10. Kurihara M: Clinical experience with UFT in Japan. Adv Exp Med Biol 339: 243-251, 1993.
11. Kawaguchi Y, Nagayama S, Masuda H and Yasuda A: Studies on the metabolism of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil coadministered orally to tumor-bearing rats. Jpn J Cancer Res 71: 889-899, 1980.
12. Kimura K, Suga S, Shimaji T, Kitamura M, Kubo K, Suzuoki Y and Isobe K: Clinical basis of chemotherapy for gastric cancer with uracil and 1-(2′-tetrahydrofury1)-5-fIuorouracil. Gastroenterol Jpn 15: 324-329, 1980.
13. Yunis AA, Arimura GK and Russin DJ: Human pancreatic carcinoma (MIAPaCa-2) in continuous culture: sensitivity to asparaginase. Int J Cancer 19: 218-235, 1977.
14. Ikeda K, Matsumoto T, Fukumoto S, Kurokawa K, Ueyama Y, Fujishige K, Tamaoki N, Saito T, Ohtake K and Ogata E: A hypercalcemic nude rat model that completely mimics human syndrome of humoral hypercalcemia of malignancy. Calcif Tissue Int 43: 97-102, 1988.
15. Carmichael J, DeGraff WG, Gazdar AF, Minna JD and Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47: 936-942, 1987.
16. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
17. Nakajima O, Ihara K, Isoda T, Matsumoto A, Komoda M, Imamura Y, Koyama Y and Kimura T: Phase I and II studies on a mixture of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil (UFT). Jpn J Cancer Chemother (in Japanese with English abstract) 7: 1558-1568, 1980.